Related Experiment Video
Updated: Jul 15, 2025
08:47
Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes
Published on: December 16, 2022
2.5K
Cardiac Contractility Modulation in Patients with Advanced Heart Failure: A Comprehensive Review of Literature
Salman Salehin1, Wissam Harmouch2, Maha Yaqub2
1Department of Cardiology, University of Texas Medical Branch, Galveston, TX.
Current Problems in Cardiology
|September 23, 2023
Summary
Cardiac contractility modulation offers a new treatment for advanced heart failure patients who do not qualify for other therapies. This innovative approach improves quality of life and prevents disease progression.
Area of Science:
- Cardiology
- Biomedical Engineering
- Heart Failure Research
Background:
- Heart failure is a leading cause of death globally, with advanced stages posing significant mortality risks despite current treatments.
- Guideline-directed medical therapy and device-based interventions improve outcomes but are not suitable for all advanced heart failure patients.
- Existing therapies like cardiac resynchronization therapy and implantable cardiac defibrillators have specific criteria that exclude many patients.
Purpose of the Study:
- To review major clinical trials on cardiac contractility modulation (CCM) for advanced heart failure.
- To evaluate CCM as a therapeutic option for patients ineligible for standard treatments.
- To highlight CCM's potential to improve functional capacity and quality of life in advanced heart failure.
Main Methods:
- Systematic review of clinical trials investigating cardiac contractility modulation.
- Analysis of patient populations with advanced heart failure, including those with preserved and reduced ejection fraction.
- Assessment of functional outcomes, quality of life, and impact on cardiac remodeling.
Main Results:
- Cardiac contractility modulation has shown promise in improving exercise capacity and quality of life.
- The therapy may mitigate pathological gene expression and prevent adverse cardiac remodeling.
- Clinical trials indicate CCM as a viable option for specific advanced heart failure cohorts.
Conclusions:
- Cardiac contractility modulation represents an innovative therapeutic strategy for advanced heart failure.
- CCM offers benefits for patients who do not meet criteria for traditional therapies.
- Further research and clinical trials are essential to establish CCM's role in heart failure management.
Related Concept Videos
01:29Cardiomyopathy V: Interprofessional Care
14
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
14
01:30Heart Failure V: Medical Management
12
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
12
01:30Cardiomyopathy II: Dilated Cardiomyopathy
11
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
11
01:26Heart Failure Drugs: Inotropic Agents
611
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
611
01:22Heart Failure VI: Adjunct Therapies
16
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
16
01:17Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K